Alvotech (ALVO)

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

Advanz Pharma Holdco Limited and Alvotech announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair®? . Alvotech

ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.

Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.

Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.

Alvotech (NASDAQ:ALVO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Balaji Prasad - Chief Strategy Officer Conference Call Participants...

Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech (ALVO) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to earnings of $0.28 per share a year ago.